search
Back to results

Photorefractive Intrastromal Corneal Crosslinking as a Treatment for Low Grade Myopia

Primary Purpose

Myopia, Corneal Crosslinking, Refractive Errors

Status
Completed
Phase
Not Applicable
Locations
Sweden
Study Type
Interventional
Intervention
4.0 mm treatment
3.5 mm treatment
Sponsored by
Umeå University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Myopia

Eligibility Criteria

18 Years - 35 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

Spherical equivalent on distance subjective refraction between -0.50D and -2.50D.

  • Astigmatism ≤ 0.75D
  • Stable myopia. Maximum change in refraction of 0.50D in the last 2 years.
  • Best corrected visual acuity of at least 0.00 logMAR (ETDRS chart).
  • Thinnest pachymetry reading ≥ 440 μm.
  • No previous ocular surgery.
  • No cognitive insufficiency interfering with the informed consent.

Exclusion Criteria:

  • History of or current condition, disease, surgery or medication with ocular effects that could affect the outcomes of the treatment.
  • Allergy to any substance or device used in the study.
  • Cognitive insufficiency interfering with the informed consent.

Sites / Locations

  • Department of Clinical Sciences/Ophthalmology, Umeå University

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

4.0 mm zone

3.5 mm zone

Arm Description

PiXL treatment with UV irradiation in a central 4.0-mm ring-shaped zone of the cornea. The area consist of three rings with a central 2-mm zone that is left untreated. The energy is higher towards the periphery of the ring-shaped area, reaching its maximum at 2-mm from the corneal centre. Pulsed UV-light, 1s on / 1s off; 30mW. For myopia of less than 0.75D, 10 J/cm2 is used, for higher levels of myopia 15J/cm2 is used.

PiXL treatment with UV irradiation in a central ring-shaped 3.5-mm zone of the cornea, with a central 1.5 mm zone that is left untreated. The illumination area consists of three rings, where the outer and inner ring are thinner than the middle ring. The maximum energy is distributed in the middle ring. Pulsed UV-light, 0.5s on / 1s off; 45mW. For myopia of less than 0.75D, a maximum of 10 J/cm2 is used, for higher levels of myopia a maximum of 15J/cm2 is used.

Outcomes

Primary Outcome Measures

Change from baseline in uncorrected visual acuity
Change from baseline in distance uncorrected visual acuity
Change from baseline in spherical equivalent
Change from baseline in spherical equivalent on subjective distance refraction

Secondary Outcome Measures

Change from baseline in corneal endothelial cell density
Change from baseline in central corneal endothelial cell density
Change from baseline in best corrected visual acuity
Change from baseline in best spectacle corrected distance visual acuity

Full Information

First Posted
June 12, 2019
Last Updated
December 9, 2020
Sponsor
Umeå University
Collaborators
Glaukos Corporation
search

1. Study Identification

Unique Protocol Identification Number
NCT03987880
Brief Title
Photorefractive Intrastromal Corneal Crosslinking as a Treatment for Low Grade Myopia
Official Title
Comparison of a 4-mm Ring Shaped and 3.5-mm Ring Shaped PiXL Protocol for Low Grade Myopia
Study Type
Interventional

2. Study Status

Record Verification Date
December 2020
Overall Recruitment Status
Completed
Study Start Date
January 22, 2018 (Actual)
Primary Completion Date
October 15, 2020 (Actual)
Study Completion Date
October 15, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Umeå University
Collaborators
Glaukos Corporation

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
To assess the improvement in refractive error and the corneal endothelial safety with a customized corneal crosslinking treatment regimen for low grade myopia. The study compares two treatment protocols, a 4.0-mm central ring-shaped zone with a 3.5-mm central ring-shaped zone in high oxygen environment without corneal epithelial debridement.
Detailed Description
The study design is a prospective, single-masked intraindividually comparing randomized controlled trial, conducted at the Department of Clinical Sciences / Ophthalmology, Umeå University Hospital, Umeå, Sweden. The study includes healthy men and women with low grade myopia, aged between 18-35 years and involves 27 participants with a myopia of -0.5 to -2.5 diopters (D) and astigmatism of ≤0.75D. All participants are treated with phototherapeutic intrastromal corneal collagen cross-linking (PiXL) without epithelial debridement (epi-on), after topical riboflavin. Both eyes are treated and randomized to receive ultraviolet (UV) light according to PiXL 4.0 mm treatment zone in one eye and PiXL 3.5 mm treatment zone in the other, which is masked to the participant. For myopia <0.75D, 10 J/cm^2 is used and for higher levels of myopia 15J/cm^2 is used. Throughout the treatment, humidified oxygen is continuously delivered around the eye using an oxygen mask to achieve an oxygen concentration of ≥95 percentage. All participants are informed about the procedures and provide oral and written consent before inclusion in the study. At baseline, each eye is examined with slit-lamp microscopy, subjective refraction, determination of uncorrected (UCVA), low contrast visual acuity at 2.5 percentage and 10 percentage contrast and best corrected (BSCVA) visual acuities using the LogMAR fast protocol and intraocular pressure (IOP) using Goldmann applanation tonometry. Under standardized, mesopic light conditions each eye is evaluated by keratometry readings, central corneal thickness and after treatment also the depth of demarcation lines, extracted from Schemipflug camera measurements, Pentacam HR® (Oculus, Inc. Lynnwood, WA). Central corneal endothelial photographs are taken with the Topcon SP-2000P specular microscope (Topcon Europe B.V., Capelle a/d Ijssel, the Netherlands), from which the corneal endothelial cell count is manually calculated from a cluster of 25 cells from each photograph. Total ocular wavefront is measured with iTrace (Tracey Technologies, Inc.). All the above mentioned examinations are reassessed at 1, 3 and 6 and 12 months after treatment. At 1 day and 1 week after treatment, solely UCVA, Auto refractor measurements, slit-lamp examination and a subjective comparison of discomfort and visual performance in each eye are evaluated.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myopia, Corneal Crosslinking, Refractive Errors, Eye Diseases

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Prospective, single-masked intraindividually comparing randomized controlled trial. Participants will be randomized to receive ultraviolet (UV) light according to protocol A in one eye and protocol B in the other, which is masked to the participant. Both eyes will be treated during the same visit. Participants are randomized utilizing a computer list of unique random numbers between 1 and 27; an even number will be treated with the 4.0-mm zone in the right eye; an uneven number with the 4.0-mm zone in the left eye.
Masking
Participant
Masking Description
The participants are not aware which eye will receive the 4.0-mm ring-shaped zone treatment and which eye will receive the 3.5-mm ring-shaped zone treatment.
Allocation
Randomized
Enrollment
27 (Actual)

8. Arms, Groups, and Interventions

Arm Title
4.0 mm zone
Arm Type
Active Comparator
Arm Description
PiXL treatment with UV irradiation in a central 4.0-mm ring-shaped zone of the cornea. The area consist of three rings with a central 2-mm zone that is left untreated. The energy is higher towards the periphery of the ring-shaped area, reaching its maximum at 2-mm from the corneal centre. Pulsed UV-light, 1s on / 1s off; 30mW. For myopia of less than 0.75D, 10 J/cm2 is used, for higher levels of myopia 15J/cm2 is used.
Arm Title
3.5 mm zone
Arm Type
Experimental
Arm Description
PiXL treatment with UV irradiation in a central ring-shaped 3.5-mm zone of the cornea, with a central 1.5 mm zone that is left untreated. The illumination area consists of three rings, where the outer and inner ring are thinner than the middle ring. The maximum energy is distributed in the middle ring. Pulsed UV-light, 0.5s on / 1s off; 45mW. For myopia of less than 0.75D, a maximum of 10 J/cm2 is used, for higher levels of myopia a maximum of 15J/cm2 is used.
Intervention Type
Procedure
Intervention Name(s)
4.0 mm treatment
Intervention Description
PiXL treatment with UV irradiation in a central 4.0-mm ring-shaped zone of the cornea.
Intervention Type
Procedure
Intervention Name(s)
3.5 mm treatment
Intervention Description
PiXL treatment with UV irradiation in a central 3.5-mm ring-shaped zone of the cornea.
Primary Outcome Measure Information:
Title
Change from baseline in uncorrected visual acuity
Description
Change from baseline in distance uncorrected visual acuity
Time Frame
1, 3, 6, 12 and 24 months after treatment
Title
Change from baseline in spherical equivalent
Description
Change from baseline in spherical equivalent on subjective distance refraction
Time Frame
1, 3, 6, 12 and 24 months after treatment
Secondary Outcome Measure Information:
Title
Change from baseline in corneal endothelial cell density
Description
Change from baseline in central corneal endothelial cell density
Time Frame
12 and 24 months after treatment
Title
Change from baseline in best corrected visual acuity
Description
Change from baseline in best spectacle corrected distance visual acuity
Time Frame
1, 3, 6, 12 and 24 months after treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Spherical equivalent on distance subjective refraction between -0.50D and -2.50D. Astigmatism ≤ 0.75D Stable myopia. Maximum change in refraction of 0.50D in the last 2 years. Best corrected visual acuity of at least 0.00 logMAR (ETDRS chart). Thinnest pachymetry reading ≥ 440 μm. No previous ocular surgery. No cognitive insufficiency interfering with the informed consent. Exclusion Criteria: History of or current condition, disease, surgery or medication with ocular effects that could affect the outcomes of the treatment. Allergy to any substance or device used in the study. Cognitive insufficiency interfering with the informed consent.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anders Behndig, MD, PhD
Organizational Affiliation
Department of Clinical Sciences/Ophthalmology, Umeå University, Umeå, Sweden
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Clinical Sciences/Ophthalmology, Umeå University
City
Umeå
ZIP/Postal Code
901 85
Country
Sweden

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Photorefractive Intrastromal Corneal Crosslinking as a Treatment for Low Grade Myopia

We'll reach out to this number within 24 hrs